Clear All
767 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA sonidegib odozmo 200 mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2015 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
NA Panobinostat Farydak 15 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan 1, 2021 In Use
J9207 ixabepilone Ixempra 1mg Chemotherapy Antitumor Antibiotic Epothilones No 2007 Jan 1, 2009 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct 1, 2017 In Use
NA venetoclax Venclexta 10 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
C9449 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Apr 1, 2015 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
N/A Zongertinib HERNEXEOS 60mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2025 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
J9052 Carmustine (Accord) Carmustine 100mg Chemotherapy Alkylating Agent Nitrosurea No 2022 Dec 7, 2023 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
N/A Dordaviprone MODEYSO 125mg Chemotherapy Protease Activator ClpP, dopamine D2 Yes 2025 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
Q5125 Filgrastim Releuko 1mcg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Sep 27, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.